Ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors have been reported in a Simcere Zaiming Pharmaceutical Co. Ltd. patent as potentially useful for the treatment of cancer.
Research at Japan Tobacco Inc. has led to the development of 6-aminopyrazolopyrimidine compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of arteriosclerosis, gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, nonalcoholic steatohepatitis (NASH), Alzheimer’s and Parkinson’s diseases.
Research at Bristol Myers Squibb Co. has led to the development of [11]-carbon-labeled compounds targeting Bruton tyrosine kinase (BTK) as positron emission tomography (PET) imaging agents for the diagnosis of multiple sclerosis.
2,4-Dihydro-3h-1,2,4-triazol-3-one P2X7 receptor antagonists have been reported in an Axxam SpA patent as potentially useful for the treatment of cognitive, eye, gastrointestinal, genitourinary and psychiatric disorders, chronic pain, neuropathic pain and neurodegeneration.
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have patented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
A recent Shenzhen Salubris Pharmaceuticals Co. Ltd. patent describes prodrugs of atrasentan that act as endothelin ETA receptor antagonists. As such, they are reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, hypertension and IgA nephropathy.
Spark Biopharma Inc. has prepared and tested stimulator of interferon genes protein (STING; TMEM173) agonists that are reported to be useful for the treatment of cancer.
RSS